NT 201: Clinical Trials

6 trials of NT 201, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 26Completed 6

Follow NT 201: new trials by email Literature Review of NT 201 trials Research Report on NT 201

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
IncobotulinumtoxinA, Placebo - Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
Phase 2CompletedMerz Therapeutics GmbH1232023-11-222026-05-05
A Study of NT 201 Doses in the Treatment of Platysma Prominence
NT 201, NT 201 Placebo - Platysma Prominence
Phase 2CompletedMerz Aesthetics GmbH732023-03-222024-10-21
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
NT 201, Placebo - Essential Tremor of the Upper Limb
Phase 2CompletedMerz Pharmaceuticals GmbH782021-02-242026-05-28
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
NT 201 - Moderate to Severe Glabellar Frown Lines
Phase 2CompletedMerz Aesthetics GmbH2412019-01-232023-11-15
Botulinum Toxin A to Treat Arm Tremor
IncobotulinumtoxinA, Placebo - Essential Tremor of the Upper Limbs
Phase 2CompletedMerz Pharmaceuticals GmbH302014-12-052021-02-18
Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy
Xeomin, Botox® - Cerebral Palsy, Spastic Paraplegia and Hemiparesis
Phase 2CompletedMerz Pharmaceuticals GmbH642014-07-012017-01-26

Conditions studied

Cerebral Palsy (1)  ·  Neuralgia, Postherpetic (1)  ·  Paraplegia (1)  ·  Paresis (1)  ·  Peripheral Nerve Injuries (1)

Sponsors

Merz Pharmaceuticals GmbH (3)  ·  Merz Aesthetics GmbH (2)  ·  Merz Therapeutics GmbH (1)

Countries

United States (4)  ·  Canada (2)  ·  Germany (2)  ·  Poland (2)  ·  Bulgaria (1)  ·  France (1)  ·  Hungary (1)  ·  Russia (1)  ·  Spain (1)

Results publications

PMID 33419261

NIH funding

2018 (1)